Category:
Biological and Medicinal Chemistry
,
Working Paper
, Title:
Gliptin Repurposing for COVID-19
, Authors:
Matthew Groves, Alexander Domling, Angel Jonathan Ruiz Moreno, Atilio Reyes Romero, Constantinos Neochoritis, Marco Velasco-Velázquez
Version 1 posted 15 April 2020
Extract found to contain search terms
Drug repurposing aims to discover novel indications for already approved 34 drugs.3 The overwhelming advantage of drug repurposing is the much faster clinical approval, due to 35 already extensive knowledge of the physicochemical properties and behavior of the drug in humans. 36 Therefore, many groups have pursued a drug repurposing approach. This has led to several promising 37 drugs which are currently tested for COVID-19 in humans, including Favipiravir, Remdesivir, HIV protease 38 inhibitors, chloroquine or Tozilizumab.4,5 So far, however, none showed more than promising activity 39 based on low numbers of patients per trial. Additionally, a combination of Lopinavir and Ritonavir 40 (Kaletra®) – effective for HIV infection – failed in ~200 severe COVID-191,151
Downloads
2
Citations